An open science pathway for drug marketing authorization-Registered drug approval.
Florian Naudet and co-authors propose a pathway involving registered criteria for evaluation and approval of new drugs.
Guardado en:
Autores principales: | Florian Naudet, Maximilian Siebert, Rémy Boussageon, Ioana A Cristea, Erick H Turner |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6fad888a133448e59cdfcac6b785c6ac |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A new approach to psychiatric drug approval in Europe.
por: Corrado Barbui, et al.
Publicado: (2013) -
Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register study.
por: Jennifer Settergren, et al.
Publicado: (2013) -
Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs
por: Hamid R. Noori, et al.
Publicado: (2018) -
Screening and Identification of Lujo Virus Entry Inhibitors From an Food and Drug Administration-Approved Drugs Library
por: Junyuan Cao, et al.
Publicado: (2021) -
The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval
por: Mariana Matias, et al.
Publicado: (2021)